Novanta Inc. (NOVTU) is not a conventional share line. The symbol represents Novanta's 6.50% Tangible Equity Units due 2028 — a listed instrument combining a prepaid stock purchase contract with an amortizing note — and it tracks the Bedford, Massachusetts-based supplier of precision medicine, robotics, laser and motion-control components to medical and advanced industrial equipment makers. The units last changed hands at $51.36, up $0.27, or 0.53%, from the prior session's close of $51.09, confirming a modestly higher open. No company news was released before the move. The advance follows a week in which the instrument lost more than 16% of its value.
No verified news or fundamental catalyst found for Friday's move. No press release, filing, analyst action or corporate announcement was published ahead of the opening print, and the tick occurred on a few hundred units, which is consistent with thin order-book mechanics rather than a fundamental re-rating. The units carried a $50.91 opening indication and then printed $51.36, a step of one dealer quote in a market where bid and ask are frequently more than 20% apart. Against a typical absolute daily move of about 1.9% across the last 69 sessions, Friday's 0.53% is roughly a quarter of normal volatility — noise, not a trend change.
The larger driver remains the third-quarter report. Revenue rose 23.1% to $305 million, organic growth reached 9.9%, adjusted EBITDA climbed 38% to a record $80 million at a 26% margin, and adjusted EPS of $1.05 beat expectations. But GAAP net income collapsed to $2 million from $10.7 million, gross margin of 47.0% missed the roughly 48% the company had guided, and shipments from the Stockport, U.K. lithography site halted after an end-user test finding, with production now expected to resume only in the first quarter of 2027. Management guided fourth-quarter adjusted EPS to $0.91–$0.96 versus a consensus near $1.02 and trimmed full-year adjusted EPS to $3.66–$3.71. A roughly 200-basis-point hit to fourth-quarter gross margin is the single most cited reason for the de-rating, and it is the reason rallies in the units have been sold so far.
The instrument has also been caught in the broader drawdown in AI-adjacent hardware. Nvidia fell 4.3% on Thursday after Jensen Huang's resignation and the appointment of CFO Colette Kress as interim chief executive, AI cloud names fell harder, and the Nasdaq Composite lost 0.40% to 25,363.75 while the S&P 500 slipped 0.34%. The related NOVT common shares, which the units economically track, fell 3.5% to $118.93 on Thursday, extending the post-earnings slide. Novanta sits squarely in the automation and robotics supply chain, so its valuation is sensitive to any sign of deceleration in capital spending on AI infrastructure and factory automation.
Volume was not elevated. The units average roughly 30,000–37,000 units a session over three months, and Friday's early turnover amounted to only a few hundred units, meaning price discovery is being set by very few trades. The move was directionally aligned with a steadier pre-market tone in large-cap technology, where Nvidia rebounded about 2.6% before the bell after its worst weekly stretch since 2012, while index futures were mixed to slightly lower. Technically, the units sit well below both their 50-day and 200-day averages near $60–$61, having failed at the $76.95 high in August, and they are trading in the lower half of a 52-week range of $47.57 to $76.95. No meaningful resistance was reclaimed with a 0.53% gain.
The score runs from 0, meaning no meaningful news and a move normal for the instrument, to 100, meaning transformative news and an extreme, rare price move. This event scores 5 out of 100. Verified news strength was effectively nil for Friday: no filing or announcement preceded the print, and the earnings shock is a week old and already reflected in price. The move was also unusually small rather than unusually large — about 0.3 times the 1.9% average absolute daily change of the past 69 sessions, and smaller than 60 of those sessions. Two weak components produce a low score.
Attention now turns to the fourth-quarter report, expected in late February, when management will update on Stockport's restart, Riverpoint Medical integration and the preliminary 2027 outlook of more than 15% reported revenue growth and over 20% adjusted EBITDA growth with at least 100 basis points of margin expansion. Consensus sits near the low end of the trimmed full-year adjusted EPS range. Risks include a delayed resumption of lithography shipments, redundant factory costs, higher interest expense on roughly $894 million of total debt, and any further contraction in AI-linked industrial demand. The 6.50% coupon component offers some income support, but the wide bid-ask spread means exits can be costly.
Tickeron's Trending AI Robots page curates the strongest performers from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the featured list changes as market conditions shift. It is a practical starting point for readers comparing systematic approaches against their own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for NOVTU crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 28 of 36 cases where NOVTU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 8 of 12 cases where NOVTU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for NOVTU turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 6 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (1.448). P/E Ratio (0.000) is within average values for comparable stocks, (5.350). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.470). NOVTU has a moderately high Dividend Yield (0.057) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (32.028).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. NOVTU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOVTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ElectronicEquipmentInstruments